1. LMP1 and LMP2 may be prognostic factors for outcome of therapy in nasopharyngeal cancers in Indonesia
- Author
-
Bambang, Hariwiyanto, Sunarto, Sastrowiyoto, Sofia, Mubarika, and Maesadji, Salugu
- Subjects
Adult ,Male ,Epstein-Barr Virus Infections ,Herpesvirus 4, Human ,Adolescent ,Nasopharyngeal Neoplasms ,Radiotherapy Dosage ,Middle Aged ,Prognosis ,Combined Modality Therapy ,Neoadjuvant Therapy ,Immunoenzyme Techniques ,Survival Rate ,Viral Matrix Proteins ,Young Adult ,Chemotherapy, Adjuvant ,Indonesia ,Case-Control Studies ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Female ,Child ,Aged ,Neoplasm Staging - Abstract
Nasopharyngeal carcinoma (NPC) is an epithelial malignancy that is invasive and metastasizes easily. In several Asian countries it is the most commonly found of the head and neck malignancies. Epstein Barr virus (EBV) infection is one of the agents causing NPC, so that expression of LMP1 and LMP2 may affect the outcome of therapy, metastasis, recurrence, and survival of NPC patients. This study aimed to investigate their expression in relation to therapy outcome and survival in a series of Indonesian NPC patients. The methods used were nested case control and Kaplan-Meier survival analysis. Differences in therapy outcome in relation to LMP1 and LMP2 expression were analyzed through chi square statistics. As a result, in post treatment NPC, there was a significant difference in therapy outcome between LMP2+ compared to LMP2⁻ (P = 0.001). There was also a significant difference in 24-months-survival between NPCs expressing LMP1+ or LMP2+ compared to those expressing LMP1⁻ or LMP2⁻.
- Published
- 2010